Shares in Value Logo
Product Review Img Vertical

Date : 08/03/2021

Why did Memphasys (ASX:MEM) shares drop by 30% today

Memphasys is a life sciences company. It is engaged in the development, manufacture and sale of pre-cast electrophoresis gels, separations equipment and consumables, analytical software and other biological products for the life science market.

Memphasys has patented technology combining electrophoresis with size exclusion-based membranes, patented hydrogels, and other polymer membranes to separate specific types of cells from fluids. Memphasys has used this technology to develop a unique device, ‘Felix’, to address male factor infertility. Felix captures high quality sperm cells from semen samples for human assisted reproductive technologies (ART).

This morning, Memphasys shares dropped 30% as the validation process for Fexis has been delayed. Memphasys Limited revealed that the validation process of its Felix Device had been delayed due to a flaw found in it, which is likely to reduce the Felix system’s effectiveness.

The data collected to date showed that the device was generally performing the function of separating good quality sperm. However, after remediation of the device, the sperm separation process is expected to improve. Memphasys has confirmed the source of the defect with its engineering and design partners, and with these partners,has already determined various possible alternative ways to address the issue.

Following internal validation, the Felix device will then be sent to partners Monash IVF and the University of Newcastle for external approvals before starting commercial rollout. Memphasys expected the Validation process to be completed by end of March 2021, however this schedule will now need to be extended, and hence the 30% dip in Memphasys shares this morning.

Looking for Assistance to Choose the Right Stocks?

Growth stocks are potentially one of the hardest to pick as there are a lot of factors that need to be considered – from industry tailwinds to financial health of the individual stocks, and a lot of little things in between them. Shares in Value research team have picked their top 3 ASX stocks to buy in 2021. Click here to download the report for free.

 

Are You Looking To Buy The Best Stocks In 2022?

Stay on top of upcoming market trends! Whether you are an SMSF investor or a young investor with your portfolio, we cover a wide range of stocks across all sectors, including mining, financials, industrials, real estate, technology, health and biotech, etc. It will give you an edge to invest and trade ASX listed stocks across large, mid and small caps with an advantage.

Get stock tips with our Market Experts. We help self-directed investors and self-managed super funds (SMSF) make smarter investment decisions and get better returns. Fill in your details and download your free Report instantly for Top 3 Dividend Stocks to buy in 2022!

 

Top 5 ASX Stocks
to Buy for Capital Growth in 2022

asx landing page
The hardest part to finding growth stocks is having an ability to understand the finer details of these companies from their valuations through to first mover advantage and having key factors on hand to make informed investment decisions.

Our experts take the guesswork out.

Download Your Free Report

By downloading this report you agree to the TERMS AND CONDITIONS and our PRIVACY POLICY

Scroll to Top

Login

By submitting this form, I agree to the TERMS AND CONDITIONS and PRIVATE POLICY

Please fill in your details to download the free dividend shares report.

We will send your report instantly. Please put your correct email address and phone number.